Sangamo Therapeutics Faces Delisting Concerns
Ticker: SGMO · Form: 8-K · Filed: May 6, 2025 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | 8-K |
| Filed Date | May 6, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
Related Tickers: SGMO
TL;DR
SGMO might be delisted - big trouble brewing.
AI Summary
Sangamo Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of April 30, 2025. The company, formerly known as Sangamo BioSciences Inc., is based in Richmond, California.
Why It Matters
This filing indicates potential issues with Sangamo Therapeutics' compliance with stock exchange listing requirements, which could impact its stock's tradability and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued operation as a publicly traded entity.
Key Players & Entities
- SANGAMO THERAPEUTICS, INC (company) — Registrant
- SANGAMO BIOSCIENCES INC (company) — Former Company Name
- April 30, 2025 (date) — Date of earliest event reported
- May 6, 2025 (date) — Filing Date
- 501 Canal Blvd., Richmond, California 94804 (address) — Principal Executive Offices
FAQ
What specific listing rule or standard has Sangamo Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that was not met, only that a notice of delisting or failure to satisfy one has been issued.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is April 30, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on May 6, 2025.
What was Sangamo Therapeutics' former company name?
Sangamo Therapeutics, Inc.'s former company name was Sangamo BioSciences Inc.
Where are Sangamo Therapeutics' principal executive offices located?
Sangamo Therapeutics' principal executive offices are located at 501 Canal Blvd., Richmond, California 94804.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding SANGAMO THERAPEUTICS, INC (SGMO).